PROK logo

PROKIDNEY CORP

PROKNASDAQ
🏆 #2914 by market capEarnings Nov 9US Equity
$462.65▲ $32.89 (+7.11%)
Simulated price
🔔
Track PROK
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 7.1%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$548M
Small Cap
📈Revenue Growth (YoY)
+1075.0%
High Growth
📊Gross Margin
-252.6%
Thin
💵FCF Margin
-19527.4%
Thin
⚖️P/S Ratio
670.0x
Expensive
Otter Score
64
Fair
No chart data available for PROK.

Trading Snapshot

Day Range
$459.93 – $468.41
52-Week Range
$1.30 – $3.48
Volume
$2.81B
Avg Volume
$2.11B
Shares Outstanding
336.3M
Next Earnings
Dec 7, 2026

Fundamentals Snapshot

Annual Revenue
$893,000
Last Q Revenue
$150,000
P/E Ratio
-2.9
P/S Ratio
670.0x
EPS (TTM)
$-0.46
Dividend Yield
0.00%
Dilution (1yr)
+9.7%

Why Investors Own PROK

  • ✓High-growth profile — revenue up +18.7% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 37% gross margin and 27% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

PROK logo

PROKIDNEY CORP

PROK
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$893K▲ +1075.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
100.0%▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$165M▼ −10.2% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$135M▼ −13.2% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
140.4M▲ +9.7% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$105M▲ +$9M YoY
StockOtter · stockotter.space

About PROKIDNEY CORP

ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship product is Renal Autologous Cell Therapy (RAC-T), a unique cellular admixture derived from a patient's own cells. RAC-T is undergoing significant clinical evaluation; it is concurrently in Phase III and Phase II trials for individuals with moderate to severe diabetic kidney disease. Furthermore, the company is conducting a Phase I clinical trial to assess RAC-T's potential for patients born with congenital anomalies affecting the kidneys and urinary tract. The company was established in 2015 and operates from its headquarters in Winston-Salem, North Carolina.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
64/100

Analyst Price Target

ⓘ
Average Target
$548.19
▲ +18.5% Upside
High Target$611.31
Low Target$511.84
Based on 12 analysts

Latest News & Updates

🚀
MarketWatch·2h ago

PROKIDNEY CORP tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Reuters·5h ago

Analysts lift PROK price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Bloomberg·1d ago

PROKIDNEY CORP announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.